DNA methylation in pulmonary fibrosis and lung cancer.

IF 2.9 3区医学 Q2 RESPIRATORY SYSTEM Expert Review of Respiratory Medicine Pub Date : 2022-05-01 DOI:10.1080/17476348.2022.2085091

Juan Duan, Baiyun Zhong, Zhihua Fan, Hao Zhang, Mengmeng Xu, Xiangyu Zhang, Yan Y Sanders

{"title":"DNA methylation in pulmonary fibrosis and lung cancer.","authors":"Juan Duan, Baiyun Zhong, Zhihua Fan, Hao Zhang, Mengmeng Xu, Xiangyu Zhang, Yan Y Sanders","doi":"10.1080/17476348.2022.2085091","DOIUrl":null,"url":null,"abstract":"Introduction: Pulmonary fibrosis is an age-related, progressive, and fatal disease with a median survival of 3-5 years after diagnosis; idiopathic pulmonary fibrosis (IPF) is the most common type. It is characterized by fibroblast proliferation and accumulation of excessive extracellular matrix. Patients with IPF are at increased risk for lung cancer. Epigenetic mechanisms are involved in lung fibrosis and cancer, and DNA methylation is critical in disease pathogenesis and progression. Therefore, studies of DNA methylation contribute to better understanding of the underlying mechanisms of these two respiratory diseases, and can offer novel diagnostic and treatment options.Areas covered: This review discusses the latest advances in our understanding of epigenetic factors related to DNA methylation that impact development of lung cancer and pulmonary fibrosis, discusses the role of DNA methylation in promoting or inhibiting these diseases, and proposes its potential clinical significance in disease diagnosis and treatment.Expert opinion: DNA methylation plays a critical role in lung cancer and fibrosis pathogenesis. DNA methylation offers a new biomarker for disease diagnosis or monitoring, and provides a new therapeutic target for treatment.","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"16 5","pages":"519-528"},"PeriodicalIF":2.9000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276636/pdf/nihms-1814013.pdf","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17476348.2022.2085091","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 9

Abstract

Introduction: Pulmonary fibrosis is an age-related, progressive, and fatal disease with a median survival of 3-5 years after diagnosis; idiopathic pulmonary fibrosis (IPF) is the most common type. It is characterized by fibroblast proliferation and accumulation of excessive extracellular matrix. Patients with IPF are at increased risk for lung cancer. Epigenetic mechanisms are involved in lung fibrosis and cancer, and DNA methylation is critical in disease pathogenesis and progression. Therefore, studies of DNA methylation contribute to better understanding of the underlying mechanisms of these two respiratory diseases, and can offer novel diagnostic and treatment options.

Areas covered: This review discusses the latest advances in our understanding of epigenetic factors related to DNA methylation that impact development of lung cancer and pulmonary fibrosis, discusses the role of DNA methylation in promoting or inhibiting these diseases, and proposes its potential clinical significance in disease diagnosis and treatment.

Expert opinion: DNA methylation plays a critical role in lung cancer and fibrosis pathogenesis. DNA methylation offers a new biomarker for disease diagnosis or monitoring, and provides a new therapeutic target for treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肺纤维化和肺癌的DNA甲基化。

肺纤维化是一种与年龄相关的进行性致命疾病，诊断后中位生存期为3-5年;特发性肺纤维化(IPF)是最常见的类型。它的特点是成纤维细胞增殖和细胞外基质过度积累。IPF患者患肺癌的风险增加。表观遗传机制涉及肺纤维化和癌症，DNA甲基化在疾病的发病和进展中至关重要。因此，DNA甲基化的研究有助于更好地了解这两种呼吸系统疾病的潜在机制，并可以提供新的诊断和治疗选择。涵盖领域:本文综述了我们对影响肺癌和肺纤维化发展的DNA甲基化相关表观遗传因素的最新认识，讨论了DNA甲基化在促进或抑制这些疾病中的作用，并提出了其在疾病诊断和治疗中的潜在临床意义。专家意见:DNA甲基化在肺癌和纤维化发病中起关键作用。DNA甲基化为疾病的诊断或监测提供了新的生物标志物，并为治疗提供了新的靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Respiratory Medicine RESPIRATORY SYSTEM-

CiteScore

6.80

自引率

2.60%

发文量

期刊介绍： Coverage will include the following key areas: - Prospects for new and emerging therapeutics - Epidemiology of disease - Preventive strategies - All aspects of COPD, from patient self-management to systemic effects of the disease and comorbidities - Improved diagnostic methods, including imaging techniques, biomarkers and physiological tests. - Advances in the treatment of respiratory infections and drug resistance issues - Occupational and environmental factors - Progress in smoking intervention and cessation methods - Disease and treatment issues for defined populations, such as children and the elderly - Respiratory intensive and critical care - Updates on the status and advances of specific disease areas, including asthma, HIV/AIDS-related disease, cystic fibrosis, COPD and sleep-disordered breathing morbidity